New Report Examines Efforts To Reduce The Impact Of Generic Competition For Popular Drug Lipitor

AARP's Public Policy Institute have released a new Rx Price Watch report examining efforts by Pfizer to reduce the impact of generic competition for the popular anti-cholesterol drug Lipitor. The report breaks down the unusually aggressive strategy reportedly undertaken by Lipitor's manufacturer before and after the drug's patent expired and discusses how the effort could become a model for other brand name drug manufacturers facing generic competition, ultimately increasing costs for consumers and publicly-funded programs like Medicare and Medicaid...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Public Health Source Type: news